Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b

NCT03319628 is registered in ClinicalTrials.gov with Mersana Therapeutics as lead sponsor.

NCT NCT03319628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03319628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Lead sponsor
Mersana Therapeutics
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
December 12, 2017
Completion date
October 31, 2024
Enrollment
523 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer metastatic, platinum resistant ovarian cancer